Overview

Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether a p38 kinase inhibitor reduces inflammation in atherosclerotic plaque
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Atorvastatin
Atorvastatin Calcium
Hydroxymethylglutaryl-CoA Reductase Inhibitors